Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Titel:
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Auteur:
Ramgopal, Moti N Castagna, Antonella Cazanave, Charles Diaz-Brito, Vicens Dretler, Robin Oka, Shinichi Osiyemi, Olayemi Walmsley, Sharon Sims, James Di Perri, Giovanni Sutton, Kenneth Sutherland-Phillips, Denise Berni, Alessandro Latham, Christine L Zhang, Feifan D'Amico, Ronald Pascual Bernáldez, Miguel Van Solingen-Ristea, Rodica Van Eygen, Veerle Patel, Parul Chounta, Vasiliki Spreen, William R Garges, Harmony P Smith, Kimberly van Wyk, Jean